Centro de Investigación Pergamino S.A
Nuestro equipo trabaja de manera colaborativa y multidisciplinaria para ofrecer un enfoque integral en el cuidado de la salud y la investigación médica. Estamos comprometidos en brindar a nuestros pacientes, la mejor atención posible y contribuir al avance de la medicina.Av. de Mayo 1115, Pergamino, Buenos Aires
Websitehttps://cip.com.ar/
Select an option
I am a doctor
I am a sponsor
Specializations
Oncología
Patients Benefits
Los estudios clínicos que están bien diseñados y bien ejecutados son el mejor enfoque para los participantes elegibles para: a. Ayudar a los demás, contribuyendo a la investigación médica b. Desempeñar un papel activo en su propia atención médica.
Our team
Medical staff
Investigadora Principal
Oncóloga Clínica - RadioterapeutaSusana Kahl
Médica ClínicaSabrina Farias
OncólogaLucia Fabiano
Médica ClínicaMaría Florencia Chamut
Médica ClínicaAna Josefina Masciotta
Legal and Administrative staff
CoordinadorDonato Cignoli
CoordinadorFlorencia Hidalgo
CoordinadorCamila Ludueña
CoordinadorValentin Parra
Open studies
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Head and neck cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more
Gastroesophageal cancer
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer - HLX22-GC-301 - Shanghai Henlius BiotechSee more
Lung cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 - KRYSTAL-7 - Mirati Therapeutics Inc.See more
